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ABSTRACT
In this report, we systematically examined the role of telomerase activity in 
lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly 
gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung 
(A549) and ovarian (SKOV3) cancer cells, transduced with the hTERT-GFP reporter, 
we then employed GFP-expression levels to fractionate these cell lines into GFP-
high and GFP-low populations. We functionally compared the phenotype of these 
GFP-high and GFP-low populations. More specifically, we now show that the cancer 
cells with higher telomerase activity (GFP-high) are more energetically activated, 
with increased mitochondrial mass and function, as well as increased glycolytic 
activity. This was further validated and confirmed by unbiased proteomics analysis. 
Cells with high telomerase activity also showed an increased capacity for stem cell 
activity (as measured using the 3D-spheroid assay) and cell migration (as measured 
using a Boyden chamber approach). These enhanced biological phenotypes were 
effectively inhibited by classical modulators of energy metabolism, which target 
either i) mitochondrial metabolism (i.e., oligomycin) or ii) glycolysis (i.e., 2-deoxy-
glucose), or iii) by using the FDA-approved antibiotic doxycycline, which inhibits 
mitochondrial biogenesis. Finally, the level of telomerase activity also determined the 
ability of hTERT-high cells to proliferate, as assessed by measuring DNA synthesis 
via EdU incorporation. Consistent with these observations, treatment with an FDA-
approved CDK4/6 inhibitor (PD-0332991/palbociclib) specifically blocked the 
propagation of both lung and ovarian CSCs. Virtually identical results were obtained 
with breast CSCs, which were also highly sensitive to palbociclib at concentrations 
in the nanomolar range. In summary, CSCs with high telomerase activity are among 
the most energetically activated, migratory and proliferative cell sub-populations. 
These observations may provide a mechanistic explanation for tumor metabolic 
heterogeneity, based on telomerase activity. FDA-approved drugs, such as doxycycline 
and palbociclib, were both effective at curtailing CSC propagation. Thus, these FDA-
approved drugs could be used to target telomerase-high proliferative CSCs, in multiple 
cancer types. Finally, our experiments also allowed us to distinguish two different 
cellular populations of hTERT-high cells, one that was proliferative (i.e., replicative 
immortality) and the other that was non-proliferative (i.e., quiescent). We speculate 
that the non-proliferative population of hTERT-high cells that we identified could be 
mechanistically involved in tumor dormancy.
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INTRODUCTION
Telomerase is a critical enzyme that serves an 
important functional role in a plethora of biological 
processes, ranging from organismal development and 
regeneration to chronological aging [1] and the onset of 
the malignant phenotype in human cancers [2–4]. Yet, 
despite years of study, many of the functions of telomerase 
still remain unknown or poorly defined. Mechanistically, 
telomerase consists of both RNA-based and proteinaceous 
components or subunits: telomerase RNA (TERC) and 
telomerase reverse transcriptase (TERT) [5]. High levels of 
telomerase expression are observed in normal stem cells [6] 
and cancer cells [7]. In both these normal and pathological 
contexts, telomerase expression functionally confers 
immortalization [8], allowing cells to bypass senescence and 
to multiply past fifty to seventy divisions [9].
Several research groups have now exploited human 
telomerase (hTERT) to allow for the enrichment of cancer 
stem-like cells (CSCs). More specifically, Yu et al., 2013 
[10], placed a 1.5-kB fragment of the hTERT promoter 
upstream of eGFP. Recombinant transduction of this hTERT-
eGFP reporter into osteosarcoma cell lines then allowed the 
purification of a telomerase enriched cell population by flow 
cytometry. They also directly showed that hTERT-high cells 
derived from an osteosarcoma cell line were more stem-like 
and underwent anchorage-independent growth. Furthermore, 
the hTERT-high osteosarcoma cell population was more 
invasive, with a greater capacity for drug-resistance and 
metastatic dissemination. Thus, this innovative approach 
to CSC enrichment has already shown great promise 
[11], but needs to be further validated and extended to the 
characterization of various epithelial cancer types, such as 
non-small cell lung cancer and ovarian carcinomas, among 
others.
In this report, we applied this general approach to 
two independent cell lines, namely A549 and SKOV3 
cells, which were originally derived from human 
cancer patients suffering from lung and ovarian cancer, 
respectively. Then, we focused on the functional and 
molecular characterization of the hTERT-high cell 
population isolated by flow cytometry. More specifically, 
we employed unbiased proteomics analysis [12, 13] and 
validation via functional metabolic studies, which allowed 
us to identify new therapeutic strategies for the eradication 
of the hTERT-high cell population.
RESULTS
Here, we used an established approach based on 
telomerase activity, to begin to dissect the role of hTERT 
in tumor cell heterogeneity. Briefly, A549 (lung) and 
SKOV3 (ovarian) cancer cell lines were stably-transduced 
with a sensitive eGFP reporter system for the fluorescent 
detection of high telomerase transcriptional activity. This 
allowed us to isolate the hTERT-high cell population by 
flow cytometry. The phenotypic behavior of GFP(+) and 
GFP(-) populations was then compared quantitatively. In 
this analysis, the GFP(+) cell population represents the 
hTERT-high cell population, while the GFP(-) cells serve 
as a critical internal control for phenotypic comparison.
hTERT-high CSCs show elevated levels of ALDH 
activity and higher mitochondrial mass
Figure 1A shows that hTERT-high cells form 
3D-spheroids (>50-μm) with a greater efficiency, up to 
2-fold higher, as observed by comparing the GFP(+) and 
GFP(-) cell populations. Virtually identical results were 
obtained with both A549 and SKOV3 cell lines, indicating 
that this is a conserved property of hTERT-high CSCs. 
Similarly, hTERT-high cells were significantly enriched 
in ALDH-activity, a well-established marker of CSCs 
(Figure 1B, 1C).
Because hTERT is mechanistically linked to 
increased mitochondrial biogenesis [11], we next 
examined the status of mitochondrial mass in hTERT-
high cells. For this purpose, we directly correlated the 
eGFP fluorescence signal (representing hTERT activity) 
with the intensity of MitoTracker Deep Red (a marker of 
mitochondrial mass). Importantly, Figure 2 demonstrates 
that GFP(+) hTERT-high cells have a higher mitochondrial 
mass, as predicted [11]. Virtually identical results were 
also obtained with another mitochondrial probe, namely 
MitoTracker Orange, which provides a measure of 
mitochondrial membrane potential (Figure 3).
As a further test of the specificity of this 
experimental system, we next employed a well-established 
telomerase inhibitor (MST-312; 1 μM) [10]. Figure 4A 
shows that treatment with MST-312 significantly reduces 
the ability of hTERT-high cells to form 3D-spheroids (a 
measure of anchorage-independent growth capacity). 
Consistent with this finding MST-312 treatment also 
reduces the expression of eGFP and mitochondrial mass 
in the hTERT-high cell population, as seen by fluorescence 
microscopy (Figure 4B). Thus, eGFP intensity does indeed 
reflect telomerase activity, and is functionally connected to 
mitochondrial mass [11].
hTERT-high CSCs are more metabolically 
active and their propagation and migration are 
inhibited by targeting mitochondrial function
To better dissect the role of hTERT activity in tumor 
cell metabolism, we next employed the Seahorse XFe96 
bioenergetic analyzer, to directly measure metabolic 
flux. For this purpose, we systematically compared 
the metabolic properties of the GFP(+) and GFP(-) cell 
populations. Figures 5 and 6 illustrate that the GFP(+) 
population is clearly more metabolically active than the 
GFP(-) cells, with significant increases in both oxygen 
consumption and glycolytic rates. This is consistent with 
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the increase in mitochondrial mass that we observed 
experimentally using the MitoTracker probes. Moreover, 
unbiased proteomics analysis of the GFP(+) and the GFP(-
) cell populations revealed that hTERT-high cells show the 
up-regulation of key mitochondrial proteins and glycolytic 
enzymes. These results are summarized in Tables 1 and 
2. Importantly, note that the expression of the MT-CO2 
protein was significantly increased (by ~4 to 6-fold) in 
GFP(+) cell populations. Since MT-CO2 is specifically 
encoded by mitochondrial DNA, this finding is indicative 
of an increased capacity for driving new mitochondrial 
biogenesis. Interestingly, a comparison of Tables 1 and 
2 indicates that the following eight metabolism-related 
proteins were commonly upregulated in hTERT-high 
cells, derived from both the A549 and SKOV3 cell 
populations (AK2, ATP5B, HSPA9, HSPD1, LDHB, 
MT-CO2, PRKDC, and PYGB) (See Supplemental Table 
1). These metabolism-related gene products are likely 
to be specific targets of hTERT in CSCs, and are mainly 
related to mitochondrial biogenesis.
To functionally validate the role of oxidative 
mitochondrial metabolism and glycolysis in the 
propagation of hTERT-high cells, we used a battery of 
well-established metabolic inhibitors, to target these 
essential metabolic pathways. To inhibit mitochondrial 
function, we employed i) oligomycin (an ATP-synthase 
inhibitor), ii) XCT790 (an ERRA/PGC1A inhibitor) 
and iii) doxycycline (an inhibitor of mitochondrial 
protein synthesis). Similarly, for inhibiting glycolysis, 
we utilized 2-deoxy-glucose (2-DG). Briefly, 2-DG 
is a chemically-modified form of glucose in which 
the 2-hydroxyl group is replaced by hydrogen; as a 
consequence, it cannot undergo further glycolysis. 
Figure 7 shows that both inhibitors of glycolysis and 
mitochondrial metabolism were similarly effective in 
halting the propagation of hTERT-high cells. This may 
be related to the fact that glycolysis inhibitors will also 
ultimately reduce oxidative mitochondrial metabolism, 
as the final product of glycolysis (pyruvate) is further 
metabolized by mitochondria.
Figure 1: Validation of the cellular models: hTERT-high cells show an increased capacity for 3D-sphere formation and 
are enriched in ALDH activity. A. 3D-sphere formation. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter 
were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. GFP(+) cells were operationally defined as those with 
the top 10% eGFP intensity, while GFP(-) cells were defined as those with the lowest 10% eGFP intensity, unless stated otherwise. The 
GFP-high and GFP-low cell populations were then plated in low-attachment plates for 3D-spheroid assays and analyzed after 5 days of 
culture. Note that GFP(+) A549 and GFP(+) SKOV3 cells both form 3D-spheroids with a near 2-fold increased efficiency, as compared to 
their corresponding GFP(-) counterparts. B and C. ALDH activity profile. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP 
reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. GFP(+) cells were operationally defined as those 
with the top 5% eGFP intensity, while GFP(-) cells were defined as those with the lowest 5% eGFP. Then, they were counter-stained with 
AldeRed to identify the ALDH(+) cell population. Representative tracings are shown in panel B, in the presence or absence of the ALDH 
inhibitor (DEAB). Panel C shows that the GFP(+) cell populations were enriched in ALDH activity relative to the GFP(-) cell population. 
Therefore, higher telomerase activity correlates with increased 3D-spheroid formation and increased ALDH activity. ALDH intensity is 
expressed as mean fluorescence intensity of 3 experiments. N=3 independent experiments, with 2 technical replicates per experiment. Bar 
graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.005, ***p < 0.0001.
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Figure 2: hTERT-high cells show a significant increase in mitochondrial mass. A549 and SKOV3 cells stably-transduced with 
the hTERT-eGFP reporter were subjected to flow cytometry to identify the GFP(+) and GFP(-) cell populations. In addition, the cells were 
also counter-stained with MitoTracker Deep Red to correlate their mitochondrial mass with GFP intensity. Five different cell populations 
with different GFP intensities were considered in this analysis. Note that panel A shows that mitochondrial mass increases with increasing 
GFP levels in hTERT-GFP A549 cells. Panel B illustrates that similar results were observed with hTERT-GFP SKOV3 cells. Therefore, 
higher telomerase activity correlates with increased mitochondrial mass in both cell lines. N=3 independent experiments, with 2 technical 
replicates for each experiment. Bar graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.001.
Figure 3: hTERT-high cells show a significant increase in mitochondrial membrane potential/activity. Cell populations 
were analyzed as outlined in Figure 2, except that MitoTracker Orange was used as a marker of mitochondrial membrane potential. Note 
that in A549 cells, mitochondrial membrane potential increases with increasing GFP levels. Therefore, higher telomerase activity correlates 
with increased mitochondrial membrane potential in A549 cells. N=3 independent experiments, 2 technical replicates per experiment. Bar 
graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.001.
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hTERT-high cells also appear to be more migratory, 
as observed by quantitatively comparing the migration 
of the GFP(+) and GFP(-) cell populations (Figure 8A). 
To test if this phenotype is strictly dependent on intact 
mitochondrial function, we examined the effects of 
two mitochondrial inhibitors, namely oligomycin and 
XCT790. Note that treatment with these mitochondrial 
inhibitors is sufficient to significantly reduce migration in 
the hTERT-high CSCs (Figure 8B, 8C).
hTERT-high CSCs are highly proliferative and 
can be effectively targeted with the CDK4/6 
inhibitor palbociclib
To better understand the role of hTERT in cell 
propagation, we assessed DNA synthesis (S-phase) in both 
the GFP(+) and GFP(-) cell populations, by employing EdU-
incorporation and FACS analysis. Remarkably, our results 
indicate that the GFP(+) cell population is the predominant 
proliferating cell population, whereas the GFP(-) population 
does not undergo significant proliferation (Figure 9). 
Importantly, these results directly show that the hTERT-high 
cells are the most significant proliferating cell population 
and, therefore, they should be targeted therapeutically.
To this end, we next evaluated the effects of a well-
established CDK4/6 inhibitor, namely palbociclib, on CSC 
propagation in A549, SKOV3 and MCF7 cells. For this 
purpose, we used 3D-spheroid formation as a measure 
of CSC-activity. Figure 10 (panels A-C) illustrates 
that palbociclib significantly inhibits the propagation 
of CSCs, in lung, ovarian and breast cancer cell lines, 
with an IC-50 near 100 nM. Thus, palbociclib and other 
Figure 4: Inhibition of telomerase activity effectively reduces 3D-spheroid formation, GFP intensity and mitochondrial 
mass. A. 3D-sphere formation A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to 
isolate the GFP(+) cell population. Then, the phenotype of the GFP(+) population was analyzed in the absence or presence of the telomerase 
inhibitor. Note that treatment with the telomerase-inhibitor MST-312 (1 μM) decreased 3D-sphere formation in GFP(+) A549 cells (1.75 
fold, left panel) and in GFP(+) SKOV3 cells (2 fold, right panel). Bar graphs are shown as the mean ± SEM; t-test, two-tailed test **p < 
0.005, ***p < 0.0001. B. Immuno-fluorescence analysis. Treatment of adherent cells with the telomerase-inhibitor MST-312 (1 μM and 5 
μM) decreases GFP and MitoTracker Deep Red staining, in a dose-dependent fashion. Representative immunofluorescence images show 
that 1 μM MST-312 causes a slight decrease of the GFP and MitoTracker signal in both cell lines. A more dramatic effect is observed after 
treatment with 5 μM MST-312 in both hTERT-GFP A549 cells and hTERT-GFP SKOV3 cells. Original magnification, 40x. Scale bar 20 
μm. Therefore, 3D-sphere formation, GFP expression and mitochondrial mass are strictly dependent on telomerase activity, as predicted.
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CDK4/6 inhibitors may be useful to clinically target the 
proliferative CSC population.
DISCUSSION
Here, we explored the contribution of hTERT-
activity to the generation and maintenance of the CSC 
population, using ovarian and lung cancer cell lines as 
a model system. To this end, we employed a sensitive 
reporter system to monitor telomerase functionally, 
by placing the hTERT endogenous promoter sequence 
upstream of eGFP. Then, we isolated hTERT-high cells 
by FACS, by collecting the GFP(+) cell population. The 
GFP(-) cell population served as a critical internal control 
for these studies. Most remarkably, hTERT-high cells 
showed significant increases in both glycolytic metabolism 
Figure 5: Mitochondrial respiration and glycolysis are both significantly enhanced in hTERT-high A549 cells. A549 
cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. 
Then, the metabolic profiles of these 2 cell populations was then analyzed quantitatively. Briefly, hTERT-GFP A549 sup-populations were 
isolated by sorting based on GFP levels, and grown as monolayers for 20 hours, prior to metabolic analysis using the Seahorse XFe96 
analyzer. A. Oxygen consumption. A representative tracing of an OCR experiment is shown in the top panel. The bar graphs in the lower 
panel show that maximal respiration is increased in GFP(+) cells as compared to GFP(-) cells by 1.32 fold. Also, the spare respiratory 
capacity is significantly higher in GFP(+) cells by 1.5 fold. Data are presented in the bar graphs as a combination of N=3 independent 
experiments. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test. B. Glycolysis rate. A representative tracing of an ECAR 
experiment is shown in the top panel. The bar graph in the lower panel shows that the glycolysis (measured after addition of glucose) is 
increased in GFP(+) cells as compared to GFP(-) cells by 1.78 fold, and the glycolytic capacity (measured after oligomycin addition) is 
increased by 1.74 fold. Data are presented in the bar graphs as a combination of N=3 independent experiments. Bar graphs are shown as the 
mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.005, ***p < 0.0001.
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and mitochondrial-driven oxygen consumption. This was 
indeed confirmed and validated further by employing 
proteomics analysis. hTERT-high cells also showed an 
enhanced ability to undergo anchorage-independent 
cell growth (3D-spheroid formation), as well as cell 
migration [13]. Both of these cellular phenotypes have 
been previously shown to be associated with increased 
“stem cell activity” in CSC populations. Importantly, 
these “stemness” phenotypes were effectively inhibited 
by treatment with compounds that halt mitochondrial 
metabolism (i.e., oligomycin, XCT790, doxycycline) 
[13–15] or ii) glycolysis (i.e., 2-deoxy-glucose) [16, 17]. 
Surprisingly, hTERT-high cells were highly proliferative, 
as evidenced by a dramatic increase in their capacity 
to undergo DNA-synthesis, when measured via EdU 
incorporation. Similarly, palbociclib (an FDA-approved 
CDK4/6 inhibitor) [18, 19] dramatically blocked the 
propagation of CSCs, as measured using 3D-spheroid 
formation as a functional assay, with an IC-50 in the 
range of 100 nM. Overall, our findings provide a new 
mechanistic appreciation for how telomerase activity 
contributes as a driver of tumor metabolic heterogeneity 
Figure 6: Mitochondrial respiration and glycolysis are both significantly enhanced in hTERT-high SKOV3 cells. SKOV3 
cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. 
Then, the metabolic profiles of these 2 cell populations was then analyzed quantitatively. Briefly, hTERT-GFP SKOV3 sup-populations 
were isolated by sorting based on GFP levels, and grown as monolayers for 20 hours, prior to metabolic analysis using the Seahorse XFe96 
analyzer. A. Oxygen consumption. A representative tracing of an OCR experiment is shown in the top panel. The bar graphs in the lower 
panel shows that basal respiration, proton leak and ATP production are all increased in GFP(+) cells as compared to GFP(-) cells. Data are 
presented in the bar graphs as a combination of N=3 independent experiments. Bar graphs are shown as the mean ± SEM; t-test, two-tailed 
test. B. Glycolysis rate. A representative tracing of an ECAR experiment is shown in the top panel. The bar graphs in the lower panel show 
glycolysis (measured after addition of glucose) is increased in GFP(+) cells as compared to GFP(-) cells by 1.5 fold, and the glycolytic 
capacity (measured after oligomycin addition) is also increased by 1.2 fold. Data are presented in the bar graphs as a combination of N=5 
independent experiments. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test. *p < 0.05, ***p < 0.0001.
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(Figure 11). Most notably, hTERT-high cells were the most 
energetic, migratory and proliferative cell population. 
Thus, FDA-approved drugs (such as doxycycline and 
palbociclib) should be considered as new therapeutic 
strategies for targeting hTERT-high cells, in various cancer 
types (Figure 11).
Similarly, several reports have now directly 
shown a connection between hTERT function and 
mitochondrial activity. This occurs through a telomerase 
and p53-based signaling pathway, which converges on 
PGC1A/B, a major mitochondrial transcription factor 
[20–22]. Specifically, aging-related studies directly 
demonstrate that impairment of hTERT function leads to 
mitochondrial decline, via p53 over-expression [23, 24], 
which ultimately inactivates PGC1A/B function [25]. 
Just the opposite occurs during cancer development, 
where p53 is often inactivated resulting in activation 
of PGC1A and mitochondrial function [26]. Thus, 
Table 1: Proteomics: Key Molecules Up-regulated in hTERT-GFP(+) A549 Lung Cancer Cells Isolated by FACS
Symbol Description Fold-Upregulation
(GPF(+)/GFP(-))
Mitochondrial-related proteins  
ALDH2 Aldehyde dehydrogenase, mitochondrial Infinity
AK2 Adenylate kinase 2, mitochondrial 27.20
ATP5B ATP synthase subunit beta 9.48
IMMT Mitochondrial inner membrane protein 9.20
MRPL49 Mitochondrial ribosomal protein L49 7.12
PRKDC DNA-dependent protein kinase catalytic subunit 6.26
HSPA9 Heat shock 70 kDa protein 9 6.00
MT-CO2 Cytochrome c oxidase subunit 2, mt-DNA encoded 3.99
NDUFS2 NADH-ubiquinone oxidoreductase 49 kDa subunit, mitochondrial 3.76
ETFA Electron transfer flavoprotein subunit alpha, mitochondrial 2.83
SLC25A10 Mitochondrial dicarboxylate carrier 2.39
ATP5O ATP synthase subunit O, mitochondrial 2.36
VDAC1 Voltage-dependent anion-selective channel protein 1 2.27
SLC25A5 Mitochondrial Carrier; Adenine Nucleotide Translocator, Member 5 1.99
HSPD1 60 kDa heat shock protein, mitochondrial 1.98
Glycolysis and PPP  
LDHB L-lactate dehydrogenase B 50.93
G6PD Glucose-6-phosphate 1-dehydrogenase 17.85
TPI1 Triosephosphate isomerase 1 17.41
PGK1 Phosphoglycerate kinase 1 9.49
ALDOA Fructose-bisphosphate aldolase 3.32
PGD 6-phosphogluconate dehydrogenase, decarboxylating 3.21
PKM2 Pyruvate kinase 1.93
Glycogen-related  
PYGB Glycogen phosphorylase, brain form 2.23
Proteomic analysis of hTERT-GFP A549 cells. Data are derived from the analysis of FACS sorted cell populations. The 
fold-increase of certain key molecules in GFP(+) cells is shown, relative to GFP(-) cells. Note that several protein targets 
related to mitochondria, glycolysis, and glycogenolysis are increased in GFP(+) cells.
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Table 2: Proteomics: Key Molecules Up-regulated in hTERT-GFP(+) SKOV3 Ovarian Cancer Cells Isolated by FACS
Symbol Description Fold-Upregulation
(GPF(+)/GFP(-))
Mitochondrial-related proteins  
MRPL15 Mitochondrial ribosomal protein L15 11.65
SLC25A10 Mitochondrial dicarboxylate carrier 10.11
DUT Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 9.48
VDAC2 Voltage-dependent anion channel 2 7.23
COX5A Cytochrome c oxidase subunit 5A, mitochondrial 7.08
MT-CO2 Cytochrome c oxidase subunit 2, mt-DNA encoded 6.08
PRKDC DNA-dependent protein kinase catalytic subunit 5.90
SHMT2 Serine hydroxymethyltransferase, mitochondrial 5.71
HSPD1 60 kDa heat shock protein, mitochondrial 5.44
FECH Ferrochelatase, mitochondrial 5.23
ATP5B ATP synthase subunit beta 4.54
SOD2 Superoxide dismutase 2 4.27
YARS2 Tyrosine--tRNA ligase, mitochondrial 4.18
DLST
Dihydrolipoyllysine-residue succinyltransferase component of 
2-oxoglutarate dehydrogenase complex, mitochondrial 4.10
TUFM Elongation factor Tu, mitochondrial 4.00
ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 3.27
PMPCA Mitochondrial-processing peptidase subunit alpha 3.25
CS Citrate synthase 3.25
MTCH2 Mitochondrial carrier homolog 2 3.10
ECI1 Enoyl-CoA delta isomerase 1, mitochondrial 2.41
AK2 Adenylate kinase 2, mitochondrial 2.41
SDHA Succinate dehydrogenase flavoprotein subunit, mitochondrial 2.39
HSPA9 Stress-70 protein, mitochondrial 2.38
ACO2 Aconitase 2, mitochondrial 1.82
IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 1.52
Glycolysis and PPP  
LDHAL6B L-lactate dehydrogenase A-like 6B 8.51
PGK2 Phosphoglycerate kinase 2 6.91
ENO3 Enolase 4.16
PKLR Pyruvate kinase isozymes R/L 3.71
ENO2 Enolase 3.56
HK1 Hexokinase-1 3.25
LDHB L-lactate dehydrogenase B 3.08
Glycogen-related  
PYGB Glycogen phosphorylase, brain form 1.63
Proteomic analysis of hTERT-GFP SKOV3 cells. Data are derived from the analysis of FACS sorted cell populations. 
The fold-increase of certain key molecules in GFP(+) cells is shown, relative to GFP(-) cells. Note that several protein 
targets related to mitochondrial metabolism and glycolysis are increased in GFP(+) cells.
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our current studies are consistent with a functional 
link between hTERT-high cells and mitochondrial 
metabolism, driving increased metabolic activation of 
this highly proliferative cell population.
Perhaps most unexpected is our observation 
that the CSC population is highly proliferative and 
can be targeted with a CDK4/6 inhibitor. However, 
this should not be too surprising, because telomerase 
activity is functionally linked to cell immortalization 
and proliferation [27], as well as escape from cell cycle 
arrest and senescence. Moreover, these experiments did 
allow us to distinguish two different cellular populations 
of hTERT-high cells, i) one that was proliferative and 
ii) the other that was non-proliferative (Figure 12). 
We speculate that the non-proliferative population of 
hTERT-high cells may be involved in tumor dormancy 
[28] and could be re-activated with the appropriate 
stimulus, driving tumor recurrence and metastasis [29]. 
Most importantly, our current work provides a novel 
strategy to potentially isolate the non-proliferative 
Figure 7: 3D-spheroid formation relies both on mitochondrial function and glycolytic metabolism. A-C. Mitochondrial 
inhibitors. Mitochondrial function is required for the efficient clonal expansion and anchorage-independent growth of CSCs. Indeed, 
oligomycin A, an inhibitor of the mitochondrial ATP synthase, inhibits 3D-sphere formation in the GFP(+) cell population isolated from 
A549 and SKOV3 cells (panel A). Complementary results were also obtained with two other well-established mitochondrial inhibitors, 
namely XCT790 (panel B) and doxycycline (panel C). XCT790 is a well-established ERRα inverse agonist that effectively blocks the 
function of PGC1A, the major mitochondrial transcription factor. Doxycycline functions as an inhibitor of mitochondrial biogenesis, by 
inhibiting mitochondrial protein synthesis at the level of the mito-ribosome. D. Inhibition of glycolysis. Glycolytic metabolism is important 
for 3D-spheroids. Note that treatment with the glycolytic inhibitor 2-deoxy-glucose (2-DG) significantly reduces sphere formation. Bar 
graphs show the mean ± SEM, t-test, two-tailed test. *p < 0.05, **p < 0.005, ***p < 0.001.
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population of hTERT-high cells, allowing further 
mechanistic studies on tumor dormancy in vitro.
Palbociclib (PD-0332991; from Pfizer) was first 
approved by the FDA on February 3, 2015 as the first-
line treatment for advanced post-menopausal ER+, 
HER2-negative breast cancer, in combination with 
letrozole [30]. It is an orally bioavailable and potent 
second generation CDK4/6 inhibitor. Mechanistically, 
it induces a G1-phase arrest in cell cycle progression. 
Remarkably, palbociclib nearly doubled progression-
free survival (PFS) in this patient population (from 
10.2 months to 20.2 months) [30]. Thus, palbociclib 
received designation as a ‘Breakthrough Therapy’ and 
gained accelerated approval from the FDA. There are 
currently at least 12 other palbociclib trials in breast 
cancer patients that are now ongoing, most of which are 
targeting advanced and metastatic disease states [30]. 
And, other CDK inhibitors are also being clinically 
developed to target metastatic disease: Ribociclib 
(LEE011; Novartis) and Abemaciclib (LY2835219; 
Eli Lilly) [30]. Since metastatic disease is thought 
to depend on the survival and propagation of CSCs, 
then it is perhaps not surprising that we observed that 
palbociclib can also be used to target the proliferative 
CSC population, in lung, ovarian and breast cancer cell 
lines, effectively halting 3D-spheroid formation, with an 
IC-50 near 100 nM. Therefore, new clinical trials using 
palbociclib to target the proliferative CSC population in 
multiple cancer types may be warranted.
Previously, we showed that palbociclib essentially 
behaves as a bonafide inhibitor of telomerase function 
in normal human fibroblasts [31]. More specifically, we 
treated hTERT-immortalized fibroblasts with palbociclib 
(0.1, 0.5 and 1 μM) for a period of 36 hours, and then 
cell lysates were prepared and subjected to immunoblot 
analysis. Importantly, treatment of hTERT-immortalized 
fibroblasts with palbociclib dramatically inhibited 
RB-phosphorylation, as expected, resulting in the up-
Figure 8: hTERT-high cells show an increased capacity for cell migration, which is strictly dependent on mitochondrial 
function. A. Cell migration. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter were subjected to flow cytometry to 
isolate the GFP(+) and GFP(-) cell populations. Then, the migratory capacity of these two cell populations was assessed using a modified 
“Boyden Chamber” assay. More specifically, the cells were allowed to migrate across an 8 μm pore uncoated membrane for 12-16 hours. 
Note that the GFP(+) cell population (derived from A549 or SKOV3 cells) shows a near 2-fold increase in migration, as compared with 
the GFP(-) cells. p<0.05 for the A549 and p<0.001 for the SKOV3 cells (Student’s t-test). B. Effects of mitochondrial inhibitors. To assess 
whether mitochondrial function is involved in cancer cell migration, mitochondrial inhibitors (either oligomycin A or XCT790) were 
placed in both the upper and lower chambers. Note that oligomycin A and XCT790 both effectively inhibited migration in the GFP(+) cell 
population. Results are shown as the mean ± SEM, t-test, two-tailed test. *p < 0.05.
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Figure 9: hTERT-high cells are highly proliferative and show an increased capacity for DNA-synthesis. We used EdU 
incorporation to monitor DNA-synthesis (S-phase) in the GFP(+) and GFP(-) cell populations. More specifically, cells were treated with 
10 uM EdU for 90 minutes and its incorporation was detected according to the recommended staining protocol. Briefly, for the detection 
of EdU, we used 405 nm excitation with a violet 450/50 nm bandpass emission filter. Measurement of total DNA content using the flow 
cytometer was achieved by using Pacific Blue (picolyl azide). In A549 cells, the GFP(+) population was 8-fold more proliferative than the 
GFP(-) cell population. Similarly, in SKOV3 cells, the GFP(+) population was 12-fold more proliferative than the GFP(-) cell population. 
Representative histograms show the separation of proliferating (S-phase) and non-proliferating cells. Bar graphs show the mean ± SEM of 
three independent experiments. Asterisks (*) denote a significant change, p<0.05.
Figure 10: Targeting CSC propagation with palbociclib, a CDK4/6 inhibitor, in lung, ovarian and breast cancers. 
Parental A549 and SKOV3 cells were seeded in low-attachment plates and treated with the indicated concentrations of PD-0332991 
(palbociclib) for five days. Then, the number of 3D-spheroids formed was quantitated. Note that palbociclib treatment very effectively 
inhibited 3D-sphere formation in A549 (panel A) and SKOV3 cells (panel B), with an IC-50 < 100 nM. 
(Continued)
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Figure 11: Telomerase-driven cancer stem-like cells are characterized by an anabolic, migratory and highly proliferative 
cellular phenotype. This schematic diagram summarizes the isolation of two distinct populations of cancer cells, based on telomerase 
transcriptional activity. A schematic diagram of the hTERT-Promoter-eGFP-Puro-R reporter construct is shown on the right. Note that the 
GFP(+) cell population shows significant increases in “stemness”, metabolic activity (both oxidative and glycolytic), cell migration and 
proliferation. As a consequence, the propagation of this cell population can be effectively targeted with metabolic inhibitors (oligomycin A, 
XCT790, doxycycline, 2-DG) or by using a CDK4/6 inhibitor (palbociclib).
Figure 10 (Continued): Virtually identical results were also obtained with MCF7 cells (panel C). Data represent three independent 
experiments. Results are shown as the mean ± SEM, t-test, two-tailed test. Asterisk (*) depicts significant change, p<0.05. *p < 0.05, 
**p < 0.005, ***p < 0.0001.
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regulation of markers of cell cycle arrest, such as CDK 
inhibitors (p16 and p21), as well as markers of senescence 
(β-galactosidase) and autophagy (LC3-I/II) [31]. Thus, 
the pharmacological induction of cell cycle arrest with 
palbociclib, a CDK4/6 inhibitor, is indeed sufficient to 
overcome the state of replicative immortality, normally 
conveyed by hTERT expression in fibroblasts. Similar 
results were also obtained by acute amino acid starvation 
of hTERT over-expressing fibroblasts, possibly explaining 
the positive benefits of caloric restriction as an anti-cancer 
therapy [31]. Thus, palbociclib could be functionally 
repurposed as an FDA-approved “telomerase inhibitor”, 
to target replicative immortality in cancer stem-like cells. 
Similarly, other groups have shown that the treatment of 
cancer cell lines with palbociclib induces the senescence 
phenotype [32, 33].
In summary, here we have used an hTERT-eGFP 
reporter system to study the functional role of telomerase 
activity in generating tumor metabolic heterogeneity. We 
observed that hTERT-high CSCs, are more energetically 
active and show an increased capacity for migration and 
cell proliferation. We propose several new therapeutic 
strategies for targeting CSCs, based on this systematic 
phenotypic analysis, by employing FDA-approved drugs 
such as doxycycline and palbociclib. These approaches 
mechanistically target energy metabolism and replicative 
immortality in CSCs.
Figure 12: Telomerase-driven cancer stem-like cells: Are they also involved in tumor dormancy? Here, we observed that the 
hTERT-high cell population could be further divided into i) proliferating and ii) non-proliferating sub-populations, using EdU incorporation 
to monitor DNA-synthesis (S-phase). We speculate that the quiescent hTERT-high CSCs could be involved in tumor dormancy. See the 
Discussion section for further elaboration on this point.
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MATERIALS AND METHODS
Materials
Non-small cell lung cancer (A549) and ovarian 
cancer (SKOV3) cell lines were obtained commercially. 
The hTERT-eGFP lenti-viral transcriptional reporter 
was custom made to our specifications by GeneCopoeia, 
and was as we previously described. Briefly, it contains 
the 1.5 kB hTERT promoter region for regulating eGFP 
expression and a puromycin-resistance cassette as a 
selectable marker for deriving stably-transduced cell 
populations. Similarly, ER(+) breast cancer cells (MCF7) 
were purchased from ATCC. Media for cell cultures 
(DMEM, D6546) was from Sigma-Aldrich. Cell culture 
media (DMEM/F12) for spheroid culture was purchased 
from Life Technologies. XCT790 was purchased from 
Tocris. The telomerase inhibitor (MST-312), oligomycin 
A, doxycycline and the CDK4/6 inhibitor palbociclib (PD-
0332991) were all obtained from Sigma-Aldrich.
Generation of A549 and SKOV3 lines, harboring 
the hTERT-GFP reporter
A549 and SKOV3 cell lines were stably-transduced 
with the viral supernatants obtained by transfecting 
packaging cells with the construct containing GFP under 
the transcriptional control of the hTERT promoter region 
(hTERT-GFP). After transduction, cancer cell lines were 
selected with puromycin for two weeks to generate 
hTERT-GFP-A549 cells and hTERT-GFP-SKOV3 cells.
Tumor 3D-spheroid culture
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) [34]. 
Briefly, 2,500 hTERT-GFP A549 cells or 5,000 hTERT-
GFP SKOV3 cells were plated with spheroids medium 
(DMEM-F12/B27/20ng/ml EGF/PenStrep), under non-
adherent conditions, in six wells plates coated with 
2-hydroxyethylmethacrylate (poly-HEMA, Sigma, 
#P3932). Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C with 5% (v/v) carbon 
dioxide/air. After five days of culture, the number of 
spheres >50 μm were counted.
Flow cytometry analysis and sorting
Cells were subjected to flow cytometric analysis 
using the Fortessa™ X-20 and the BD Accuri™ C6. 
The GFP(+) (top 10%) and GFP(-) (lowest 10%) cell 
populations were separated and collected by using the BD 
FACSAria™ III and BD Influx™ cell sorter. Data were 
analyzed using FlowJo software (Tree Star, Ashland, OR).
AldeRed ALDH detection assay
The AldeRed with 588-A ALDH Detection 
Assay (SCR150, Millipore) was used, following the 
manufacturer's instructions.
Mitochondrial staining of live cells with 
MitoTracker probes
To evaluate the mitochondrial mass and activity, 
adherent cells were stained with MitoTracker Deep 
Red (M22426, Life Technologies) or in suspension 
with MitoTracker Orange CM-H2TMRos (M7511, Life 
Technologies), respectively. Lyophilized MitoTracker 
was first dissolved in DMSO to generate a 1 μM stock 
solution that was diluted into serum-free DMEM at a final 
concentration of 25 nM and 100 nM respectively. Briefly, 
cells were cultured for 48 hours and then stained with 
MitoTracker for 15 minutes at 37°C. Cells were washed 
in PBS and analysed by FACS.
Immunofluorescence analysis
After six days of treatment with MST-312, the 
cells were subjected to immunofluorescence analysis. 
Briefly, the cells were incubated with MitoTracker Deep 
Red for 20 minutes, and, after washing, were fixed in 
4% paraformaldehyde for 15 minutes. Then, cells were 
permeabilized for 10 minutes with PBS containing 0.2% 
BSA and 0.1% Tween-20. Next, a blocking step with 
5% of BSA in PBS was followed by an incubation of 90 
minutes with the GFP Tag Antibody, conjugated to the 
Alexa Fluor 488 (A21311, Life Technologies). Finally, 
slides were washed, stained with DAPI and mounted. 
Images were acquired using a fluorescent microscope.
Seahorse metabolic flux analysis
Extracellular acidification rates (ECAR) and 
oxygen consumption rates (OCR) were measured using 
the Seahorse XFe96 bioenergetic analyzer (Seahorse 
Bioscience, MA, USA). GFP(+) and GFP(-) cell 
populations were maintained in DMEM supplemented 
with 10% FBS (Fetal Bovine Serum), 2 mM GlutaMAX, 
and 1% Pen-Strep. Fifteen thousand cells were seeded 
for A549 and ten thousand for SKOV3 into XF96-
well cell culture plates per well, and incubated at 
37°C in a 5% CO2 humidified atmosphere. After 20 
hours, cells were washed in pre-warmed XF assay 
media, as previously described [13]. ECAR and OCR 
measurements were normalized by cell number. Data 
sets were analyzed using Seahorse XFe-96 software and 
Excel software, using Student t-test calculations. All 
experiments were performed with six replicates each, 
and repeated three times independently.
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Semi-quantitative proteomics analysis
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLCnano system (Thermo Scientific, 
formerly Dionex), The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
technical replicates were analyzed for each sample 
(GFP(+) versus GFP(-); top 10% versus lowest 10%).
Migration assay
Transwell-24 wells with uncoated permeable 
support and 8-μm pores were used (Corning). Thirty-
thousand (A549) or twenty-thousand (SKOV3) viable 
tumor cells were seeded per well, in the upper chamber 
and incubated in 5% CO2 at 37°C. The upper side of the 
filter was filled with DMEM medium containing 0.1% 
BSA. The lower chamber was filled with complete culture 
medium containing 10% FBS as chemo-attractant. After 
an overnight period, non-migrated cells were removed 
from the upper surface of the membrane by scrubbing 
with cotton swabs. Inserts were stained with crystal violet 
(HT90132, Sigma-Aldrich). All functional experiments 
were performed in triplicates. Values for migration were 
obtained by counting five fields per membrane (objective 
40X) and represent the average of three independent 
experiments. Oligomycin A and XCT790 were placed in 
both lower and upper chambers.
Proliferation assay
The Click-iTR Plus EdU Flow Cytometry Assay was 
used for determining the percentage of S-phase cells (DNA 
synthesis) in the cell populations (Pacific Blue™ picolyl 
azide, C10636, Molecular Probes Life Technologies), 
according to the manufacture’s protocol.
Statistics
Data are presented as the mean ± SEM. The 
student’s t-test and ANOVA were used where appropriate. 
P < 0.05 was considered statistically significant.
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